APCure is a biotechnology company developing Immunotherapy products based on BacVac (for Bacterial Vaccine), an innovative technology that uses a live, harmless, bioengineered bacterial vector to cure cancers. BacVac is a unique technology that reduces tumor defenses and induce a strong anti-tumor immune response. In other words, BacVac teaches the patient own immune system to fight cancer.
| Website | http://www.apcure.com |
| Revenue | $6 million |
| Employees | 2 (1 on RocketReach) |
| Founded | 2012 |
| Address | 30, rue Pré-Gaudry, Lyon, Auvergne-Rhone-Alpes 69007, FR |
| Phone | +33 4 26 84 69 63 |
| Technologies |
JavaScript
,
HTML
,
Font Awesome
+5 more
(view full list)
|
| Industry | Business Services, Biotechnology |
| Keywords | Immunotherapy, Cancer Immunotherapy, Cancer Treatment, Vaccine Technology, Cancer Research, Biotechnology, Immuno-Oncology, Clinical Trials, Oncology, Bioengineering, Drug Development, Biopharmaceutical, Pharmaceutical, Medicine, Healthcare |
| Competitors | APEX Biologix, Regenexx Physicians, CellResearch Corporation, Advanced Biologics, Healing Solutions Essential Oils, PhoenixBio, Darrow Stem Cell Institute, Plasmatech, Be Well Labs, Celerity Pharmaceuticals, LLC +25 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies, NAICS Code 5417 Companies |
Looking for a particular APCure employee's phone or email?
The APCure annual revenue was $6 million in 2026.
Laurent Buffat is the CEO of APCure.
1 people are employed at APCure.
APCure is based in Lyon, Auvergne-Rhone-Alpes.
The NAICS codes for APCure are [54171, 54, 541, 541714, 5417].
The SIC codes for APCure are [873, 87].